Utrecht Centre for

Pharmaceutical Policy and Regulation

June 9th, 2015

Adjusted Indirect Treatment Comparison of the Bioavailability of WHO-Prequalified First-Line Generic Antituberculosis Medicines
June 9th, 2015

Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications.
June 9th, 2015

Regulatory review: How do agencies ensure the quality of decision making?
June 9th, 2015

Expediting patients’ access to medicines by improving the predictability of drug development and the regulatoryapproval process.
June 9th, 2015

Pharmacovigilance in Africa.
June 9th, 2015

Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study.
June 9th, 2015

Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection.
June 9th, 2015

The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia.